wrong calculation
top 20 could now control over 25%...
Maybe the option conversion was a defensive move against a predator .
So if the board have protected the company from an opportunustic bid they can now negotiate a fair deal (in other words get set for a licencing agreement in the not too distant future).
- Forums
- ASX - By Stock
- SBP
- in the paper tomorrow
SBP
solbec pharmaceuticals limited
in the paper tomorrow, page-5
Add SBP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
Previous Video
Next Video
SPONSORED BY The Market Online